187 related articles for article (PubMed ID: 17875790)
1. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790
[TBL] [Abstract][Full Text] [Related]
2. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
4. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
9. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
10. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
Xiong DS; Zheng MJ; Liu YX; Xu YF; Wang JH; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):673-8. PubMed ID: 15973988
[TBL] [Abstract][Full Text] [Related]
11. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ
Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
[TBL] [Abstract][Full Text] [Related]
12. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
13. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
15. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.
Hofmeister JK; Cooney D; Coggeshall KM
Blood Cells Mol Dis; 2000 Apr; 26(2):133-43. PubMed ID: 10753604
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.
Le Doussal JM; Martin M; Gautherot E; Delaage M; Barbet J
J Nucl Med; 1989 Aug; 30(8):1358-66. PubMed ID: 2787847
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
